None
Quote | resTORbio Inc. (NASDAQ:TORC)
Last: | $2.28 |
---|---|
Change Percent: | -3.8% |
Open: | $2.38 |
Close: | $2.28 |
High: | $2.46 |
Low: | $2.21 |
Volume: | 850,283 |
Last Trade Date Time: | 09/15/2020 04:55:40 pm |
News | resTORbio Inc. (NASDAQ:TORC)
Adicet Bio completes its previously announced merger with resTORbio (NASDAQ: TORC ) and the new combined company will operate under the name 'Adicet Bio, Inc.'. More news on: resTORbio, Inc., Merger & acquisition news, Read more ...
- Adicet Emerges as a Leading Allogeneic Gamma Delta T Cell Therapy Company Focused on Oncology - -Trading to Commence on September 16, 2020 on The Nasdaq Global Market Under Ticker Symbol “ACET”- MENLO PARK, Calif. and BOSTON, Sept. 15, 2020 (GLOBE NEWSWIRE) -...
Message Board Posts | resTORbio Inc. (NASDAQ:TORC)
Subject | By | Source | When |
---|---|---|---|
$torc $2.28 ? 0.0 (0.00%) | Taurus69 | investorshub | 03/28/2021 2:12:59 AM |
$torc $5 with news | Taurus69 | investorshub | 02/25/2021 10:06:46 PM |
$torc $2.28 ? 0.0 (0.00%) | Taurus69 | investorshub | 02/25/2021 10:05:48 PM |
$torc $2.28 ? 0.0 (0.00%) | Taurus69 | investorshub | 02/06/2021 11:26:43 PM |
$torc $2.28 ? 0.0 (0.00%) | Taurus69 | investorshub | 01/17/2021 4:51:26 AM |
News, Short Squeeze, Breakout and More Instantly...
- Adicet Emerges as a Leading Allogeneic Gamma Delta T Cell Therapy Company Focused on Oncology - -Trading to Commence on September 16, 2020 on The Nasdaq Global Market Under Ticker Symbol “ACET”- MENLO PARK, Calif. and BOSTON, Sept. 15, 2020 (GLOBE NEWSWIRE) -...
MENLO PARK, Calif. , Aug. 5, 2020 /PRNewswire/ -- Adicet Bio, Inc., a privately-held biopharmaceutical company, today announced that it has received a $10 million milestone payment from Regeneron associated with ADI-002 meeting key preclinical development goals, in accordance with the t...
BOSTON, July 30, 2020 (GLOBE NEWSWIRE) -- resTORbio, Inc. (Nasdaq: TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent or treat aging-related diseases, today provided a corporate update and reported financial results ...